PDE4A and psoriasis vulgaris: To further validate the potential of PDE4 inhibitors against CHCHD10S59Lmediated toxicity, we also tested the first generation PDE4 inhibitor, Rolipram(9, 10), and another approved drug, Apremilast, which is prescribed for plaque psoriasis or psoriatic arthritis(9, 11, 12).